Hasan David M, Starke Robert M, Gu He, Wilson Katina, Chu Yi, Chalouhi Nohra, Heistad Donald D, Faraci Frank M, Sigmund Curt D
From the Department of Neurological Surgery (D.M.H., H.G., K.W., Y.C.) and Departments of Pharmacology and Internal Medicine, Carver College of Medicine (Y.C., D.D.H., F.M.F., C.D.S.), University of Department of Internal Medicine, Iowa; Department of Neurological Surgery, University of Virginia, Charlottesville (R.M.S.); Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA (N.C.); and Department of Internal Medicine, Iowa City Veterans Affairs Healthcare System (F.M.F.).
Hypertension. 2015 Jul;66(1):211-20. doi: 10.1161/HYPERTENSIONAHA.115.05332. Epub 2015 Apr 27.
Vascular inflammation plays a critical role in the pathogenesis of cerebral aneurysms. Peroxisome proliferator-activated receptor γ (PPARγ) protects against vascular inflammation and atherosclerosis, whereas dominant-negative mutations in PPARγ promote atherosclerosis and vascular dysfunction. We tested the role of PPARγ in aneurysm formation and rupture. Aneurysms were induced with a combination of systemic infusion of angiotensin-II and local injection of elastase in (1) mice that received the PPARγ antagonist GW9662 or the PPARγ agonist pioglitazone, (2) mice carrying dominant-negative PPARγ mutations in endothelial or smooth muscle cells, and (3) mice that received the Cullin inhibitor MLN4924. Incidence of aneurysm formation, rupture, and mortality was quantified. Cerebral arteries were analyzed for expression of Cullin3, Kelch-like ECH-associated protein 1, nuclear factor (erythroid-derived 2)-like 2, NAD(P)H dehydrogenase (quinone)1 (NQO1), and inflammatory marker mRNAs. Neither pioglitazone nor GW9662 altered the incidence of aneurysm formation. GW9662 significantly increased the incidence of aneurysm rupture, whereas pioglitazone tended to decrease the incidence of rupture. Dominant-negative endothelial-specific PPARγ did not alter the incidence of aneurysm formation or rupture. In contrast, dominant-negative smooth muscle-specific PPARγ resulted in an increase in aneurysm formation (P<0.05) and rupture (P=0.05). Dominant-negative smooth muscle-specific PPARγ, but not dominant-negative endothelial-specific PPARγ, resulted in significant decreases in expression of genes encoding Cullin3, Kelch-like ECH-associated protein 1, and nuclear factor (erythroid-derived 2)-like 2, along with significant increases in tumor necrosis factor-α, monocyte chemoattractant protein-1, chemokine (C-X-C motif) ligand 1, CD68, matrix metalloproteinase-3, -9, and -13. MLN4924 did not alter incidence of aneurysm formation, but increased the incidence of rupture (P<0.05). In summary, endogenous PPARγ, specifically smooth muscle PPARγ, plays an important role in protecting from formation and rupture of experimental cerebral aneurysms in mice.
血管炎症在脑动脉瘤的发病机制中起关键作用。过氧化物酶体增殖物激活受体γ(PPARγ)可预防血管炎症和动脉粥样硬化,而PPARγ的显性负性突变则会促进动脉粥样硬化和血管功能障碍。我们测试了PPARγ在动脉瘤形成和破裂中的作用。通过全身输注血管紧张素-II和局部注射弹性蛋白酶,在以下小鼠中诱导动脉瘤形成:(1)接受PPARγ拮抗剂GW9662或PPARγ激动剂吡格列酮的小鼠;(2)在内皮细胞或平滑肌细胞中携带显性负性PPARγ突变的小鼠;(3)接受Cullin抑制剂MLN4924的小鼠。对动脉瘤形成、破裂和死亡率进行量化。分析脑动脉中Cullin3、 Kelch样ECH相关蛋白1、核因子(红系衍生2)样2、NAD(P)H脱氢酶(醌)1(NQO1)和炎症标志物mRNA的表达。吡格列酮和GW9662均未改变动脉瘤形成的发生率。GW9662显著增加了动脉瘤破裂的发生率,而吡格列酮则倾向于降低破裂的发生率。显性负性内皮特异性PPARγ未改变动脉瘤形成或破裂的发生率。相比之下,显性负性平滑肌特异性PPARγ导致动脉瘤形成增加(P<0.05)和破裂增加(P=0.05)。显性负性平滑肌特异性PPARγ而非显性负性内皮特异性PPARγ导致编码Cullin3、 Kelch样ECH相关蛋白1和核因子(红系衍生2)样2的基因表达显著降低,同时肿瘤坏死因子-α、单核细胞趋化蛋白-1、趋化因子(C-X-C基序)配体1、CD68、基质金属蛋白酶-3、-9和-13显著增加。MLN4924未改变动脉瘤形成的发生率,但增加了破裂的发生率(P<0.05)。总之,内源性PPARγ,特别是平滑肌PPARγ,在保护小鼠实验性脑动脉瘤的形成和破裂方面发挥重要作用。